Ramy Kayal

Sexual dysfunctions in breast cancer patients: evidence in context.

G. Ciliberto, B. Chiofalo, G. Sanguineti, 2023, Sexual medicine reviews.

Planned neck dissection after chemoradiotherapy in advanced oropharyngeal squamous cell cancer: the role of US, MRI and FDG-PET/TC scans to assess residual neck disease.

G. Sanguineti, L. Marucci, R. Covello, 2014, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence

N. Tinari, G. Ciliberto, G. Sanguineti, 2020 .

Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by 90Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma

M. Marino, D. Giannarelli, F. Pisani, 2015, Experimental Hematology & Oncology.

Cervical lymphadenopathy: can the histogram analysis of apparent diffusion coefficient help to differentiate between lymphoma and squamous cell carcinoma in patients with unknown clinical primary tumor?

R. Covello, F. Piludu, R. Pellini, 2018, La radiologia medica.

Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial

G. Ciliberto, G. Sanguineti, P. Marchetti, 2020, Cancers.

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience

S. Barni, N. Tinari, G. Ciliberto, 2018, Journal of cellular physiology.

Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients

A. Giordano, P. Marchetti, A. Amodio, 2016, Journal of Cancer.

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios

G. Ciliberto, G. Sanguineti, P. Marchetti, 2019, Journal of Cancer.

Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim

A. Mengarelli, F. Palombi, G. Regazzo, 2024, Annals of hematology.